Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
Guanethidine chemical structure
|ATC code |
|Molecular weight||198.309 g/mol|
|Elimination half-life||1.5 days|
|Routes of administration|
Side effects[edit | edit source]
Pharmacology[edit | edit source]
Guanethidine is transported by uptake 1 into the presynaptic terminal. (In this it competes with noradrenaline so can potentiate exogenously applied noradrenaline). Once inside the terminal it blocks the release of noradrenaline in response to arrival of an action potential. Spontaneous release is not affected.
Uses[edit | edit source]
Guanethidine was once a mainstay for hypertension resistant to other agents, but it is now rarely used in the US due to side effects and because substantially better drugs are available. It is still licensed in some countries, e.g. UK, for the rapid control of blood pressure in a hypertensive emergency.
See also[edit | edit source]
References[edit | edit source]
- Joyce PI, Rizzi D, Caló G, Rowbotham DJ, Lambert DG (November 2002). The effect of guanethidine and local anesthetics on the electrically stimulated mouse vas deferens. Anesth. Analg. 95 (5): 1339–43, table of contents.